What type of study is this?

December 8, 2025BloodOpen Access

CAR T cell therapy referral patterns and characteristics of patients with relapsed or refractory (R/R) large B cell lymphoma (LBCL) in the United States

View Full Paper

Ask AI

Bookmark

Authors

Retrospective cohort study finds 80% of patients with large B cell lymphoma do not receive CAR T cell therapy, highlighting access gaps.

Overall, 15% of patients with large B cell lymphoma received CAR T cell therapy at CAR T sites.
Referral rates for CAR T therapy were 19% at second line and decreased to 13% at fifth line.
Analysis utilized real-world claims data to assess patients’ treatment journeys and referral patterns.
Access barriers indicate a need for improved referral pathways and CAR T site availability to enhance treatment equity.

Shadman et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark